ENANTA PHARMACEUTICALS INC (ENTA) Stock Price, Quote, News and Overview
NASDAQ:ENTA - Nasdaq - US29251M1062 - Common Stock - Currency: USD
ENTA Quote, Performance and Key Statistics
5.05
-0.39 (-7.17%)
The current stock price of ENTA is 5.05 USD. In the past month the price increased by 8.84%. In the past year, price decreased by -60.08%.
ENTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.22 | 331.06B | ||
| AMGN | AMGEN INC | 13.03 | 145.40B | ||
| GILD | GILEAD SCIENCES INC | 12.65 | 121.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.6 | 60.30B | ||
| ARGX | ARGENX SE - ADR | 323.74 | 37.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.10B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.06B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.77B | ||
| NTRA | NATERA INC | N/A | 21.14B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.97B | ||
| BIIB | BIOGEN INC | 7.38 | 17.12B |
Related stock screener links
About ENTA
Company Profile
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 131 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The firm has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The firm also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Company Info
ENANTA PHARMACEUTICALS INC
4 Kingsbury Avenue
Watertown MASSACHUSETTS 02472 US
CEO: Jay R. Luly
Employees: 131
Phone: 16176070800
ENANTA PHARMACEUTICALS INC / ENTA FAQ
What is the stock price of ENANTA PHARMACEUTICALS INC today?
The current stock price of ENTA is 5.05 USD. The price decreased by -7.17% in the last trading session.
What is the ticker symbol for ENANTA PHARMACEUTICALS INC stock?
The exchange symbol of ENANTA PHARMACEUTICALS INC is ENTA and it is listed on the Nasdaq exchange.
On which exchange is ENTA stock listed?
ENTA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ENANTA PHARMACEUTICALS INC stock?
13 analysts have analysed ENTA and the average price target is 17.17 USD. This implies a price increase of 240% is expected in the next year compared to the current price of 5.05. Check the ENANTA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ENANTA PHARMACEUTICALS INC worth?
ENANTA PHARMACEUTICALS INC (ENTA) has a market capitalization of 107.72M USD. This makes ENTA a Micro Cap stock.
How many employees does ENANTA PHARMACEUTICALS INC have?
ENANTA PHARMACEUTICALS INC (ENTA) currently has 131 employees.
What are the support and resistance levels for ENANTA PHARMACEUTICALS INC (ENTA) stock?
ENANTA PHARMACEUTICALS INC (ENTA) has a resistance level at 5.84. Check the full technical report for a detailed analysis of ENTA support and resistance levels.
Is ENANTA PHARMACEUTICALS INC (ENTA) expected to grow?
The Revenue of ENANTA PHARMACEUTICALS INC (ENTA) is expected to decline by -11.83% in the next year. Check the estimates tab for more information on the ENTA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ENANTA PHARMACEUTICALS INC (ENTA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ENTA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ENTA, evaluating the profitability, health, valuation and growth aspects
- ENANTA PHARMACEUTICALS INC (ENTA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ENANTA PHARMACEUTICALS INC (ENTA) Sales and EPS estimates to see what analysts future expectations are.
- ENANTA PHARMACEUTICALS INC (ENTA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ENANTA PHARMACEUTICALS INC (ENTA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ENANTA PHARMACEUTICALS INC (ENTA) Stock Chart to make your own analysis
- ENANTA PHARMACEUTICALS INC (ENTA) Latest news and press-releases to stay up to date.
Does ENANTA PHARMACEUTICALS INC (ENTA) stock pay dividends?
ENTA does not pay a dividend.
When does ENANTA PHARMACEUTICALS INC (ENTA) report earnings?
ENANTA PHARMACEUTICALS INC (ENTA) will report earnings on 2025-05-12, after the market close.
What is the Price/Earnings (PE) ratio of ENANTA PHARMACEUTICALS INC (ENTA)?
ENANTA PHARMACEUTICALS INC (ENTA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.95).
What is the Short Interest ratio of ENANTA PHARMACEUTICALS INC (ENTA) stock?
The outstanding short interest for ENANTA PHARMACEUTICALS INC (ENTA) is 14.09% of its float. Check the ownership tab for more information on the ENTA short interest.
ENTA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ENTA. When comparing the yearly performance of all stocks, ENTA is a bad performer in the overall market: 83.45% of all stocks are doing better.
ENTA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ENTA. ENTA has a bad profitability rating. Also its financial health evaluation is rather negative.
ENTA Financial Highlights
Over the last trailing twelve months ENTA reported a non-GAAP Earnings per Share(EPS) of -4.95. The EPS increased by 24.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.1% | ||
| ROE | -93.84% | ||
| Debt/Equity | 0.01 |
ENTA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to ENTA. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 15.9% and a revenue growth -11.83% for ENTA